Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer

Goeckenjan, G; Sitter, H.; Thomas, Michael; Branscheid, D.; Flentje, Michael; Griesinger, Frank; Niederle, N.; Stuschke, Martin; Blum, Torsten; Deppermann, KM; Ficker, Joachim H.; Freitag, Lutz; Lübbe, A. S.; Reinhold, Thomas; Späth‐Schwalbe, E.; Ukena, D.; Wickert, Monique; Wolf, Mark A.; Andreas, Stefan; Allmendinger, Thomas; Baum, R. P.; Baysal, Birol; Beuth, Josef; Bickeböller, Heike; Böcking, Alfred; Bohle, RM; Brüske, Irene; Burghuber, Otto Chris; Dickgreber, N.; Diederich, Sven; Dienemann, Hendrik; Eberhardt, Wilfried; Eggeling, Stephan; Fink, T.; Fischer, Berthold; Franke, Markus; Friedel, Godehard; Gauler, Thomas; Gütz, S; Haŭtmann, Hŭbert; Hellmann, A; Hellwig, Dirk; Herth, Felix J.F.; Heußel, CP; Hilbe, Wolfgang; Hoffmeyer, Frank; Horneber, Markus; Huber, RM; Hübner, Julia; Kauczor, HU; Kirchbacher, Klaus; Kirsten, D; Kraus, Thomas; Lang, SM; Martens, Uwe M.; Mohn-Staudner, Andrea; Müller, K.-M.; Müller‐Nordhorn, Jacqueline; Nowak, Dennis; Ochmann, Uta; Passlick, Bernward; Petersen, Iver; Pirker, Robert; Pokrajac, Boris; Reck, Martin; Riha, Susanne; Rübe, Claudia E.; Schmittel, Alexander; Schönfeld, Nicolas; Schütte, W.; Serke, Monika; Stamatis, Georgios; Steingräber, M; Steins, Martin; Stoelben, Erich; Swoboda, L; Teschler, Helmut; Tessen, H. W.; Weber, Marianne; Werner, A; Wichmann, HE; Wimmer, Elisabeth; Witt, Christian; Worth, H.

doi:10.1055/s-0030-1255961

Cited by 132 publications

(72 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients had given informed consent following the 2000 revision of the guidelines of the Declaration of Helsinki and the local Ethics Committee of the Medical Faculty Heidelberg. Pre-operative and follow-up assessments were performed according to the guidelines of the German Respiratory Society last published in 2010 [21]. The stage was determined according to the seventh edition of the TNM classification of malignant tumours [3].…”

Section: Methodsmentioning

confidence: 99%

Stage-specific embryonic antigen-4is expressed in basaloid lung cancer and associated with poor prognosis

et al. 2012

View full text Add to dashboard Cite

Basaloid carcinoma represents a rare variant of nonsmall cell lung cancer (NSCLC), which has shown a poor prognosis in a number of studies. Although it is considered to derive from a pluri-or multipotent pulmonary stem cells, little is known about the expression and clinical significance of stem cell antigens in this variant.Stage-specific embryonic antigen-4 (SSEA-4) was analysed by immunohistochemistry in 38 patients with resected early-stage basaloid NSCLC who had a median follow-up of 72.9 months. The expression of SSEA-4 was related to clinico-pathological characteristics, to the expression of the adult stem cell antigens CD117, CD133 and breast cancer resistance protein 1 (BCRP1), and to prognosis.SSEA-4 was positive in 37% of the specimens and showed no association with clinicopathological characteristics or the expression of adult stem cell antigens. Cox proportional hazards regression analysis revealed a 6.0-fold increased risk of relapse (p50.001) and a 4.2-fold increased risk of disease-related mortality (p50.017) in SSEA-4-positive patients, while SSEA-4-negative patients showed a prognosis comparable with that of other early-stage NSCLC.SSEA-4 is expressed in a fraction of basaloid NSCLC and is associated with poor prognosis.

show abstract

Section: Methodsmentioning

confidence: 99%

Stage-specific embryonic antigen-4is expressed in basaloid lung cancer and associated with poor prognosis

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Despite improvements in diagnostics and therapy, 5-year overall survival rates of patients with lung cancer remain bleak (15-18%) [1]. In patients without metastatic involvement, multidisciplinary approaches including surgery, radiotherapy and chemotherapy can achieve cure for some patients.…”

Section: Introductionmentioning

confidence: 99%

Intracellular ATP-Binding Cassette Transporter A3 is Expressed in Lung Cancer Cells and Modulates Susceptibility to Cisplatin and Paclitaxel

Overbeck

Hupfeld²,

Krause³

et al. 2013

Oncology

View full text Add to dashboard Cite

Patients with advanced-stage bronchial cancer benefit from systemic cytostatic therapy, in particular from regimens integrating cisplatin and taxanes. However, eventual disease progression leads to a fatal outcome in most cases, originating from tumor cells resisting chemotherapy. We here show that the intracellular ATP-binding cassette transporter A3 (ABCA3), previously recognized as critical for the secretion of surfactant components from type 2 pneumocytes, is expressed in non-small-cell lung cancer (NSCLC) cells. With some heterogeneity in a given specimen, expression levels detected immunohistochemically in primary cancer tissue were highest in adenocarcinomas and lowest in small cell lung cancers. Genetic silencing of ABCA3 in the NSCLC cell line models A549, NCI-H1650 and NCI-H1975 significantly increased tumor cell susceptibility to the cytostatic effects of both cisplatin (in all cell lines) and paclitaxel (in two of three cell lines). Taken together, ABCA3 emerges as a modulator of NSCLC cell susceptibility to cytostatic therapy.

show abstract

“…Despite of advantages in new technologies and developing of new drugs contributing to a much earlier diagnosis and a more sufficient treatment, NSCLC remains a life threatening disease. The overall 5-year survival for NSCLC patients is still low and even in the early stages of the disease the recurrence rate is relatively high [2,3]. The poor prognosis is due to the highly aggressive behavior expressed by fast progressive tumor growth and early metastasis.…”

Section: Introductionmentioning

confidence: 99%

Serum Level of CC-Chemokine Ligand 18 is Increased in Patients with Non-small-cell Lung Cancer and Correlates with Survival Time in Adenocarcinomas

et al. 2012

View full text Add to dashboard Cite

CC-chemokine ligand18 (CCL18) ismainly expressed by alternativelyactivated macrophages and DCs and plays an important role in lung fibrosis, arthritis and other diseases. Here CCL18 was measured in sera of 31 healthy volunteers and 170 patients with lung cancer and correlatedthese data with histology, tumor stage and clinicalparameters. Mean CCL18 serum levelofthe patients with non-small-cell lung cancer was 150(857) ng/ml vs. 32(61) ng/ml in the healthy control group. Patient groups differ significantly according their histology (adenocarcinoma 143(528) ng/ml vssquamous cell carcinoma 187(857) ng/ml, p,0.02). In addition, we found a significant difference between patients with lower versus higher T-stage (p,0.003). Receiver operating characteristic (ROC) analyses revealed a cutoff point of 83 ng/ml (area under the curve (AUC): 0.968; p,0.0001) to discriminate between healthy controls and non-small-cell lung cancer patients. ROC analyses to discriminate between patients, who died because of cancer related death and those who died for other reasons did not lead to a valid AUC. To stratify the tumor patients, a criterion value plot was performed leading to a point of equal sensitivity and specificity (54%) of 162 ng/ml. Patients with a CCL18 serum level higher than 160 ng/ml had a mean survival time of 623 days. In contrast, those in patients with a baseline level between 83 ng/ml and 160 ng/ml the mean survival time was 984 days (p,0.005). Survival-analysis revealed in adenocarcinoma a mean survival of 1152 days in the group below 83 ng/ml. In the median group the mean survival time was 788 days and in the group with the highest levels the mean survival time was 388 days (p,0.001). In contrast, we found no correlation between the FEV1 and the CCL18 baseline level. In conclusion, in patients suffering from adenocarcinoma increased serum CCL18 levels predict a diminished survival time.

show abstract

Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer

Cited by 132 publications

References 6 publications

Stage-specific embryonic antigen-4is expressed in basaloid lung cancer and associated with poor prognosis

Stage-specific embryonic antigen-4is expressed in basaloid lung cancer and associated with poor prognosis

Intracellular ATP-Binding Cassette Transporter A3 is Expressed in Lung Cancer Cells and Modulates Susceptibility to Cisplatin and Paclitaxel

Serum Level of CC-Chemokine Ligand 18 is Increased in Patients with Non-small-cell Lung Cancer and Correlates with Survival Time in Adenocarcinomas

Contact Info

Product

Resources

About